Otsuka Pharmaceutical
Présence
Otsuka Holdings fait partie des...
Otsuka Holdings est une société cotée sous le symbole boursier 4578 (JP).
Otsuka Holdings a une présence directe dans 10 pays.Otsuka Holdings a 25 filiales dont Astex, Astex Pharmaceuticals et Cambridge Isotope Laboratories.
Elles sont en:
- Pharmacie54%
- Équipements médicaux27%
- Autre19%
Dirigeants
Voir l'organigramme avec ses 170 principaux dirigeants
Biographies les plus recherchées chez Otsuka Pharmaceutical
- Makoto Inoue, President and Representative Director
- Tatsuo Higuchi, Chairman and Representative Director
- Hiroshi Sugawara, Board Member
Créer une alerte
pour suivre les mouvements de dirigeants chez Otsuka Pharmaceutical.
Pharmacie
Otsuka Holdings a 1 869 concurrents dont Pfizer (Etats—Unis), Sanofi (France) et Johnson & Johnson (Etats—Unis).
Actualités en fusion/acquisition en Pharmacie.
- AstraZeneca has announced the acquisition of Fusion Pharma (publié le 23 mars 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (publié le 19 mars 2024).
- Frontier Medicines vient d'annoncer une levée de fonds de 80 millions de dollars. (publié le 27 février 2024).
Contacts en Pharmacie
Actualités
Derniers communiqués de presse par Otsuka Pharmaceutical
- FACEDUO Emotion Recognition Training VR now available - Support for those with developmental conditions such as autism spectrum disorder (ASD), which makes it difficult to read emotions -｜News Releases | Otsuka Pharmaceutical Co., Ltd.
- U.S. Food and Drug Administration (FDA) Clearance of Rejoyn® First Prescription Digital Therapeutic Authorized in the U.S. for the Adjunctive Treatment of Major Depressive Disorder (MDD) symptoms｜News Releases | Otsuka Pharmaceutical Co., Ltd.
- Otsuka Works with Verily to Launch Longitudinal Mental Health Registry to Advance Novel Research in Psychiatry in the U.S.｜News Releases | Otsuka Pharmaceutical Co., Ltd.
- Otsuka and Lundbeck submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD｜News Releases | Otsuka Pharmaceutical Co., Ltd.
- Novartis receives approval in Japan for Entresto® Granular Tablets for Pediatric Use, a formulation dedicated for pediatric patients with chronic heart failure｜News Releases | Otsuka Pharmaceutical Co., Ltd.
- Abilify Maintena® 960mg (aripiprazole) approved in the EU as the first once-every-two-months long-acting injectable for the maintenance treatment of schizophrenia｜News Releases | Otsuka Pharmaceutical Co., Ltd.
- Submission of an Application for the First Hematological Malignancies Gene Panel Test in Japan｜News Releases | Otsuka Pharmaceutical Co., Ltd.
- Otsuka and Sumitomo Revise License Agreement - Otsuka holds exclusive rights to develop, manufacture, and commercialize ulotaront and SEP-380135 worldwide - ｜News Releases | Otsuka Pharmaceutical Co., Ltd.
- Otsuka Pharmaceutical Enters into Cooperation Agreement on Heat Illness Prevention with Environmental Restoration and Conservation Agency｜News Releases | Otsuka Pharmaceutical Co., Ltd.
- Otsuka and Lundbeck Present New Data Analyses on the Efficacy of REXULTI® (brexpiprazole) for Agitation Associated with Dementia Due to Alzheimer's Disease ｜News Releases | Otsuka Pharmaceutical Co., Ltd.
- Voir plus de communiqués de presse Close
Réseaux sociaux à propos de Otsuka Pharmaceutical
- Otsuka Pharmaceutical sur Wikipédia, Google News & Yahoo Finance en 1-click
- Otsuka Pharmaceutical sur LinkedIn, Twitter & YouTube en 1-click
Entrer en contact
Contacter par email ses dirigeants dont Hisanori Maei 
Appelez Otsuka Pharmaceutical au +81 36...
